Immune response characteristics following emergency vaccination of pigs against foot-and-mouth disease

被引:30
作者
Barnard, AL
Arriens, A
Cox, S
Barnett, P
Kristensen, B
Summerfield, A
McCullough, KC [1 ]
机构
[1] Inst Virol & Immunoprophylaxis, Dept Immunol, CH-3147 Mittelhausern, Switzerland
[2] Inst Anim Hlth, Woking GU2 40NF, Surrey, England
[3] Royal Vet & Agr Univ, Lab Virol & Immunol, DK-1870 Frederiksberg C, Denmark
关键词
FMDV; emergency-vaccination; Th1/Th2-responses;
D O I
10.1016/j.vaccine.2004.07.034
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Pigs were vaccinated with the emergency inactivated foot-and-mouth disease virus (FMDV) vaccine-water-in-oil-in-water emulsion with Montanide ISA206-known to protect after 3-5 days. Peripheral blood leukocyte (PBL) sub-populations did not differ between vaccinates and controls post-vaccination. There was neither lymphopenia nor inflammatory reaction. FMDV-specific antibody and T lymphocyte activity developed in the vaccinates. Virus-induced Th1-like cytokine protein and mRNA (IFNgamma and IL-2) were identified, particularly IFNgamma. Th2-like cytokine protein and mRNA (IL-4 and IL-6) were also induced in an FMDV-specific manner. IL-10 was induced by both virus and mock antigen. The current emergency FMDV vaccine induces a diverse immune defence network-innate. and both Th1-like and Th2 responses-without adverse reactions such as lymphopenia or inflammatory responses. (C) 2004 Elsevier Ltd. All rights reserved.
引用
收藏
页码:1037 / 1047
页数:11
相关论文
共 47 条
[1]   Further studies on the early protective responses of pigs following immunisation with high potency foot and mouth disease vaccine [J].
Barnett, PV ;
Cox, SJ ;
Aggarwal, N ;
Gerber, H ;
McCullough, KC .
VACCINE, 2002, 20 (25-26) :3197-3208
[2]   International bank for foot-and-mouth disease vaccine: Assessment of Montanide ISA 25 and ISA 206, two commercially available oil adjuvants [J].
Barnett, PV ;
Pullen, L ;
Williams, L ;
Doel, TR .
VACCINE, 1996, 14 (13) :1187-1198
[3]   Protective immune response to 16 kDa immunoreactive recombinant protein encoding the C-terminal VP1 portion of foot and mouth disease virus type Asia 1 [J].
Bayry, J ;
Prabhudas, K ;
Gopalakrishna, S ;
Patil, PK ;
Ramakrishna, C ;
Misra, LD ;
Suryanarayana, VVS .
MICROBIOLOGY AND IMMUNOLOGY, 1999, 43 (08) :765-771
[4]   Interspecies major histocompatibility complex-restricted Th cell epitope on foot-and-mouth disease virus capsid protein VP4 [J].
Blanco, E ;
McCullough, K ;
Summerfield, A ;
Fiorini, J ;
Andreu, D ;
Chiva, C ;
Borrás, E ;
Barnett, P ;
Sobrino, F .
JOURNAL OF VIROLOGY, 2000, 74 (10) :4902-4907
[5]   WORKSHOP STUDIES ON MONOCLONAL-ANTIBODIES REACTIVE AGAINST PORCINE MYELOID CELLS [J].
BLECHA, F ;
KIELIAN, T ;
MCVEY, DS ;
LUNNEY, JK ;
WALKER, K ;
STOKES, CR ;
STEVENS, K ;
KIM, YB ;
CHU, RM ;
CHEN, TS ;
MURTAUGH, MP ;
CHOI, C ;
MOLITOR, TW ;
MCCULLOUGH, K ;
PESCOVITZ, MD .
VETERINARY IMMUNOLOGY AND IMMUNOPATHOLOGY, 1994, 43 (1-3) :269-272
[6]   NEW APPROACHES TO VACCINATION AGAINST FOOT-AND-MOUTH-DISEASE [J].
BROWN, F .
VACCINE, 1992, 10 (14) :1022-1026
[7]   Emergency vaccination of sheep against foot-and-mouth disease: protection against disease and reduction in contact transmission [J].
Cox, SJ ;
Barnett, PV ;
Dani, P ;
Salt, JS .
VACCINE, 1999, 17 (15-16) :1858-1868
[8]   EMERGENCY VACCINATION AGAINST FOOT-AND-MOUTH-DISEASE - RATE OF DEVELOPMENT OF IMMUNITY AND ITS IMPLICATIONS FOR THE CARRIER STATE [J].
DOEL, TR ;
WILLIAMS, L ;
BARNETT, PV .
VACCINE, 1994, 12 (07) :592-600
[9]   INTERNATIONAL BANK FOR FOOT-AND-MOUTH-DISEASE VACCINE - STABILITY STUDIES WITH VIRUS CONCENTRATES AND VACCINES PREPARED FROM THEM [J].
DOEL, TR ;
PULLEN, L .
VACCINE, 1990, 8 (05) :473-478
[10]   CROSS-REACTIVE AND SEROTYPE-SPECIFIC ANTIBODIES AGAINST FOOT-AND-MOUTH-DISEASE VIRUS GENERATED BY DIFFERENT REGIONS OF THE SAME SYNTHETIC PEPTIDE [J].
DOEL, TR ;
DOEL, CMFA ;
STAPLE, RF ;
DIMARCHI, R .
JOURNAL OF VIROLOGY, 1992, 66 (04) :2187-2194